[go: up one dir, main page]

WO2011159124A3 - Ｉｎｔｅｒｌｅｕｋｉｎ-６ 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물 - Google Patents

Ｉｎｔｅｒｌｅｕｋｉｎ-６ 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물 Download PDF

Info

Publication number
WO2011159124A3
WO2011159124A3 PCT/KR2011/004436 KR2011004436W WO2011159124A3 WO 2011159124 A3 WO2011159124 A3 WO 2011159124A3 KR 2011004436 W KR2011004436 W KR 2011004436W WO 2011159124 A3 WO2011159124 A3 WO 2011159124A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitory activity
activity against
preparation
pharmaceutical composition
composition containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2011/004436
Other languages
English (en)
French (fr)
Other versions
WO2011159124A2 (ko
Inventor
박혜영
김영국
최정호
김진아
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ewha Womans University
Original Assignee
Ewha Womans University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ewha Womans University filed Critical Ewha Womans University
Priority to US13/805,136 priority Critical patent/US8614240B2/en
Publication of WO2011159124A2 publication Critical patent/WO2011159124A2/ko
Publication of WO2011159124A3 publication Critical patent/WO2011159124A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 인터루킨-6(IL-6) 저해 활성을 가지는 화학식 1로 표시되는 벤즈옥사졸 유도체, 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물을 제공한다. 본 발명에 따른 화학식 1로 표시되는 화합물은 인터루킨-6 저해활성이 우수하여, 인터루킨-6 활성 이상에 의해 유발된 질환의 예방 및 치료에 유용하게 사용될 수 있다.
PCT/KR2011/004436 2010-06-18 2011-06-17 Ｉｎｔｅｒｌｅｕｋｉｎ-６ 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물 Ceased WO2011159124A2 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/805,136 US8614240B2 (en) 2010-06-18 2011-06-17 Benzoxazole derivatives having inhibitory activity against interleukin-6, preparation method thereof, and pharmaceutical composition containing the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020100057844A KR101372721B1 (ko) 2010-06-18 2010-06-18 Ｉｎｔｅｒｌｅｕｋｉｎ―６ 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
KR10-2010-0057844 2010-06-18

Publications (2)

Publication Number Publication Date
WO2011159124A2 WO2011159124A2 (ko) 2011-12-22
WO2011159124A3 true WO2011159124A3 (ko) 2012-05-03

Family

ID=45348763

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/004436 Ceased WO2011159124A2 (ko) 2010-06-18 2011-06-17 Ｉｎｔｅｒｌｅｕｋｉｎ-６ 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물

Country Status (3)

Country Link
US (1) US8614240B2 (ko)
KR (1) KR101372721B1 (ko)
WO (1) WO2011159124A2 (ko)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014038882A1 (ko) * 2012-09-07 2014-03-13 한국생명공학연구원 신규 화합물 및 이의 인터루킨-1베타 또는 인터루킨-6 저해 용도
KR101666727B1 (ko) * 2013-12-30 2016-10-14 이화여자대학교 산학협력단 신경세포의 분화 또는 재생, 신경손상 또는 신경질환의 치료 효과가 있는 신규한 물질, 이의 제조방법 및 이를 포함하는 약학 조성물
EP3310767B1 (en) 2015-06-22 2020-07-22 Actelion Pharmaceuticals Ltd. 2,5-disubstituted benzoxazole and benzothiazole compounds as nadph oxidase 4 inhibitors
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
KR102337399B1 (ko) * 2019-10-02 2021-12-09 주식회사 클로소사이언스 항노화 유전자 klotho의 발현을 유도하는 화합물 및 이의 용도
CN116887866A (zh) 2020-12-03 2023-10-13 巴特尔纪念研究院 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法
CN117157280A (zh) * 2021-04-01 2023-12-01 克洛索科学公司 包含诱导抗老化基因klotho的表达的化合物的用于预防或治疗慢性肾脏疾病的组合物
WO2022211574A1 (ko) * 2021-04-01 2022-10-06 주식회사 클로소사이언스 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 만성신장질환의 예방 또는 치료용 조성물
KR102375097B1 (ko) * 2021-04-01 2022-03-17 주식회사 클로소사이언스 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 퇴행성 신경질환의 예방 또는 치료용 조성물
JP2024516108A (ja) 2021-04-07 2024-04-12 バテル・メモリアル・インスティテュート 非ウイルス性担体を同定および使用するための迅速な設計、構築、試験、および学習技術
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
KR102841314B1 (ko) * 2023-10-24 2025-08-01 경희대학교 산학협력단 신규한 우울증 치료용 벤즈옥사졸 화합물
WO2025122954A1 (en) 2023-12-08 2025-06-12 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004085425A1 (en) * 2003-03-21 2004-10-07 Amgen Inc Fused azoles such as 2,5-disubstituted benzimidazoles, benzoxazoles and benzothiazoles as kinase inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2011514T3 (da) 1997-03-21 2012-03-26 Chugai Pharmaceutical Co Ltd Forebyggende eller terapeutisk middel til sensibiliserede-T-celle-medierede sygdomme omfattende IL-6-antagonist som en aktiv bestanddel

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004085425A1 (en) * 2003-03-21 2004-10-07 Amgen Inc Fused azoles such as 2,5-disubstituted benzimidazoles, benzoxazoles and benzothiazoles as kinase inhibitors
US7531553B2 (en) * 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NORIHINO NISHIMOTO ET AL.: "Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X-ray reader-blinded randomised controlled trial of tocilizumab", ANN RHEUM DIS, vol. 66, 2007, pages 1162 - 1167 *

Also Published As

Publication number Publication date
WO2011159124A2 (ko) 2011-12-22
KR101372721B1 (ko) 2014-03-14
US20130090480A1 (en) 2013-04-11
KR20110137868A (ko) 2011-12-26
US8614240B2 (en) 2013-12-24

Similar Documents

Publication Publication Date Title
WO2011159124A3 (ko) Ｉｎｔｅｒｌｅｕｋｉｎ-６ 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
WO2017123884A8 (en) Heterocyclic compounds as rsv inhibitors
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
WO2012047017A3 (ko) 2,3-디히드로-이소인돌-1-온 유도체 및 이를 포함하는 조성물
TN2016000581A1 (en) Heteroaryl compounds useful as inhibitors of sumo activating enzyme
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
IN2014KN00948A (ko)
EP4609866A3 (en) Oxysterols and methods of use thereof
WO2013066839A3 (en) Compounds and methods
WO2013066835A3 (en) Compounds and methods
UA105229C2 (uk) Фармацевтичний склад
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
MX2013011589A (es) Metodos y composiciones para tratar enfermedad de parkinson.
HK1255500A1 (zh) 氧固醇及其使用方法
WO2012048129A3 (en) Inhibitors of polo-like kinase
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
PH12013500301A1 (en) Oxadiazole inhibitors of leukotriene production
HK1206021A1 (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
PH12015500211B1 (en) 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
PH12013500644A1 (en) Co-crystals and salts of ccr3-inhibitors
TN2012000092A1 (en) Therapeutic agent for mood disorders
WO2013093931A3 (en) Novel prodrugs of phenolic drugs
WO2014036502A3 (en) Tetracycline compounds
WO2014102592A3 (en) Oxime/substituted quinoxaline-type piperidine compounds and uses thereof
WO2012128582A3 (en) A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11795990

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13805136

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 11795990

Country of ref document: EP

Kind code of ref document: A2